
1. j med chem. 2018 jul 26;61(14):6236-6246. doi: 10.1021/acs.jmedchem.8b00643. epub
2018 jul 17.

2,4-diaminoquinazolines dual toll-like receptor (tlr) 7/8 modulators the
treatment hepatitis b virus.

embrechts w(1), herschke f(1), pauwels f(1), stoops b(1), last s(1), pieters
s(1), pande v(1), pille g(1), amssoms k(1), smyej i(1), dhuyvetter d(1),
scholliers a(1), mostmans w(1), van dijck k(1), van schoubroeck b(1), thone t(1),
de pooter d(1), fanning g(1), jonckers thm(1), horton h(1), raboisson p(1),
mcgowan d(1).

author information: 
(1)janssen infectious diseases diagnostics bvba , turnhoutseweg 30 , 2340 beerse 
, belgium.

a novel series 2,4-diaminoquinazolines identified potent dual toll-like
receptor (tlr) 7 8 agonists reduced off-target activity. the
stereochemistry amino alcohol found influence tlr7/8
selectivity ( r) isomer resulting selective tlr8 agonism. lead
optimization toward dual agonist afforded (
s)-3-((2-amino-8-fluoroquinazolin-4-yl)amino)hexanol 31 potent analog, being
structurally different previously described dual agonists ( mcgowan j. med. 
chem. 2016 , 59 , 7936 ). pharmacokinetic pharmacodynamic (pk/pd) studies
revealed desired high first pass profile aimed limiting systemic cytokine 
activation. vivo pharmacodynamic studies lead compound 31 demonstrated
production cytokines consistent tlr7/8 activation mice cynomolgus 
monkeys ex vivo inhibition hepatitis b virus (hbv).

doi: 10.1021/acs.jmedchem.8b00643 
pmid: 29965759  [indexed medline]

